These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 25831770)
21. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist. Boudreaux KJ; Chang SS BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172 [No Abstract] [Full Text] [Related]
22. [Tamoxifen: modern drug therapy of estrogen-dependent breast tumors]. Jovanović-Mićić D; Beleslin DB; Nikolić SS Med Pregl; 1996; 49(7-8):287-90. PubMed ID: 8926945 [TBL] [Abstract][Full Text] [Related]
23. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. Nahleh Z Future Oncol; 2008 Feb; 4(1):15-21. PubMed ID: 18240997 [TBL] [Abstract][Full Text] [Related]
27. New treatment for advanced prostate cancer. FDA Consum; 2004; 38(2):4. PubMed ID: 15101352 [No Abstract] [Full Text] [Related]
28. Cancer treatment-induced bone loss in breast and prostate cancer. Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443 [TBL] [Abstract][Full Text] [Related]
29. Prostate cancer drugs. Making sense of the options. Mayo Clin Health Lett; 2003 Aug; 21(8):4-5. PubMed ID: 12971308 [No Abstract] [Full Text] [Related]
30. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. Mitsiades N Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973 [TBL] [Abstract][Full Text] [Related]
31. New approaches to reverse resistance to hormonal therapy in human breast cancer. Weinberg OK; Marquez-Garban DC; Pietras RJ Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421 [TBL] [Abstract][Full Text] [Related]
32. Malignant mixed Müllerian tumor of the uterus associated with tamoxifen therapy for breast cancer. Magnani KK; Dubey S; Rai S Indian J Pathol Microbiol; 2010; 53(4):886-7. PubMed ID: 21045469 [No Abstract] [Full Text] [Related]
33. Endogenous estrogen levels, bone mineral density and estrogen receptor status in breast cancer. Altundag K; Altundag O; Gunduz M Breast Cancer Res Treat; 2005 Jan; 89(2):213. PubMed ID: 15692765 [No Abstract] [Full Text] [Related]
34. [Endocrine therapy in breast cancer: efficacy and adverse events]. Odermatt R; Wolfer A; Zaman K Rev Med Suisse; 2013 May; 9(387):1090-4. PubMed ID: 23757917 [TBL] [Abstract][Full Text] [Related]
36. [An overview of clinical trials in endocrine therapy for cancer]. Hinotsu S; Ohasi Y; Akaza H Gan To Kagaku Ryoho; 1996 May; 23(6):689-94. PubMed ID: 8645019 [TBL] [Abstract][Full Text] [Related]
37. [Action of SERM and SAS (tibolone) on breast tissue]. Gompel A; Jacob D; de Chambine S; Mimoun M; Decroix Y; Rostene W; Poitout P Contracept Fertil Sex; 1999 May; 27(5):368-75. PubMed ID: 10401183 [TBL] [Abstract][Full Text] [Related]
38. Adjuvant endocrine therapy for premenopausal hormone receptor-positive breast cancer; much done, more to do. Higgins MJ; Wolf AC Oncology (Williston Park); 2009 Jan; 23(1):40, 42, 44. PubMed ID: 19283920 [No Abstract] [Full Text] [Related]
39. Novel drugs targeting the androgen receptor pathway in prostate cancer. Mateo J; Smith A; Ong M; de Bono JS Cancer Metastasis Rev; 2014 Sep; 33(2-3):567-79. PubMed ID: 24390422 [TBL] [Abstract][Full Text] [Related]
40. Estrogen receptor: is it predictive for response to cytotoxic as well as hormonal therapy? Pritchard KI Breast Cancer Res Treat; 2011 Jun; 127(2):587-8. PubMed ID: 19191022 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]